[Skip to Content]

ranibizumab

Intravitreal ranibizumab injection for the treatment of choroidal neovascularisation secondary to pathological myopia

College Statement The Royal College of Ophthalmologists welcomes the decision by The National Institute for Health and Care Excellence (NICE) to recommend Ranibizumab 0.5 mg intravitreal injection as an option for treating visual impairment due to choroidal neovascularisation secondary to pathological myopia. Prior to this decision there has been limited / variable access to anti-VEGF

Intravitreal Ranibizumab injection for treatment of MO secondary to RVO

College Statement The Royal College of Ophthalmologists welcomes the decision by the National Institute for Health and Care Excellence (NICE) to recommend 0.5mg ranibizumab intravitreal injection as an option for the treatment of macular oedema secondary to central retinal vein occlusion (CRVO) and selected cases of branch retinal vein occlusion (BRVO) when laser has either

Review of ranibizumab in patients with diabetic macular oedema

Statement on the rapid review of the technology appraisal of the use of intravitreal ranibizumab in patients with diabetic macular oedema (DMO) Review of Ranibizumab for DMO

NICE rapid review of previous technology appraisal – intravitreal ranibizumab with DMO

College Statement The National Institute of Clinical Excellence (NICE) has completed a rapid review of the previous technology appraisal of the use of intravitreal ranibizumab in patients with diabetic macular oedema. The new guidance document on ranibizumab for diabetic macular oedema, (TA274), published on 27 February 2013, recommends that patients with DMO can be commenced